Welcome to our dedicated page for Abcellera Biologics SEC filings (Ticker: ABCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AbCellera Biologics Inc. filings document regulatory disclosures for a clinical-stage biotechnology company developing antibody-based medicines. Form 8-K reports cover financial and operational results, Regulation FD presentations, ABCL635 clinical program updates, patent settlement and license matters, and leadership or board changes.
Proxy materials describe governance matters, board composition, committee service, director independence, executive compensation, equity awards, and shareholder voting items. The filing record also reflects the company’s status as a British Columbia registrant with securities listed on Nasdaq under the symbol ABCL.
AbCellera Biologics Inc. director Michael R. Hayden received a grant of share options covering 111,701 common shares. The options have an exercise price of $5.27 per share, expire on June 11, 2036, and represent compensation rather than an open-market purchase.
The options vest and become exercisable at the company’s 2027 Annual General Meeting, subject to his continuous service with AbCellera through that date. Following this award, he holds options on a total of 1,011,544 underlying common shares directly.
AbCellera Biologics Inc. director Stephen Quake received a grant of 111,701 share options giving the right to buy an equal number of common shares at an exercise price of $5.27 per share. After this grant, Quake holds share options for a total of 306,633 common shares.
The options vest and become exercisable at the company’s 2027 Annual General Meeting, provided Quake continues to serve the company through that date. This is a compensation-related award rather than an open-market stock trade.
AbCellera Biologics Inc. director John S. Montalbano received a grant of share options giving him the right to buy 111,701 common shares at an exercise price of $5.27 per share. These options vest and become exercisable at the 2027 Annual General Meeting, as long as he continues serving the company. After this grant, he holds 1,141,544 share options in total.
AbCellera Biologics Inc. reported the results of its annual shareholder meeting held on June 11, 2026. Shareholders elected Class III directors John S. Montalbano and Stephen R. Quake to terms ending at the 2029 annual meeting. As of the April 15, 2026 record date, 305,264,947 common shares were outstanding and entitled to vote.
Shareholders also ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, and approved, on a non-binding advisory basis, the compensation of the company’s named executive officers (Say-on-Pay). No other matters were submitted for a vote.
AbCellera Biologics Inc. filed an initial ownership report for Sandor Victor. The filing identifies him as a director of the company, not an officer and not a ten percent owner. This Form 3 does not report any share transactions or holdings, serving only as a baseline disclosure.
AbCellera Biologics Inc. announced that its Board of Directors appointed Dr. Victor Sandor as a new independent director. He will serve until the next annual meeting of shareholders and until a successor is elected and qualified, or earlier resignation or removal.
The Board determined that Dr. Sandor is independent under Nasdaq rules and the company’s Corporate Governance Guidelines. He will participate in AbCellera’s Non-Employee Director Compensation Policy on the same terms as other non-employee directors and currently has not been appointed to any Board committees.
AbCellera highlighted Dr. Sandor’s extensive oncology drug development background, including leadership roles at Array BioPharma, Incyte, Biogen, and AstraZeneca, where he contributed to multiple cancer therapy approvals. The company describes itself as a clinical-stage biotechnology firm focused on first-in-class antibody-based medicines across several therapeutic areas.
AbCellera Biologics Inc.’s Chief Financial Officer Andrew Booth exercised share options to acquire 250,000 Common Shares at an exercise price of $0.19 per share. Following this transaction, he directly owns 445,600 Common Shares.
The filing also reports 130,959 Common Shares held indirectly through his spouse. The exercised options vested in substantially equal annual installments over six years, with the first tranche vesting on June 15, 2017, subject to his continuous service to the company.
AbCellera Biologics Inc. director John S. Montalbano reported buying additional company stock. On May 14, 2026, he made an open-market purchase of 20,000 Common Shares at $4.77 per share. After this transaction, he holds 241,000 Common Shares directly and 5,000 Common Shares indirectly through his spouse.
AbCellera Biologics reported a net loss of $43.2M for the quarter ended March 31, 2026, slightly improved from $45.6M a year earlier. Revenue nearly doubled to $8.3M, driven by higher research fees, but remains modest relative to expenses.
Research and development spending rose to $46.7M as the company advanced internal programs ABCL635, ABCL575 and ABCL688. Sales, general and administrative costs fell to $12.3M, reflecting lower legal and overhead spending. AbCellera ended the quarter with $504.7M in cash, cash equivalents and marketable securities, providing a sizable runway despite increased cash use.
The company highlighted progress in its transition toward an internal clinical pipeline, including positive interim Phase 1 data for ABCL635 and ongoing Phase 2 enrollment, while continuing to rely on government contributions and a large securities portfolio to fund operations.
AbCellera Biologics Inc. reported first quarter 2026 results and highlighted positive interim Phase 1 data for its lead program ABCL635. Revenue rose to $8.3 million from $4.2 million in Q1 2025, while net loss narrowed slightly to $43.2 million or $(0.14) per share.
The company increased research and development spending to $46.7 million and reduced sales, general and administrative expenses to $12.3 million. AbCellera ended the quarter with approximately $655 million in total available liquidity, including $531 million in cash, cash equivalents and marketable securities and about $124 million in non‑dilutive government funding.
Interim Phase 1 data for ABCL635, a potential first‑in‑class antibody targeting NK3R for menopausal vasomotor symptoms, showed a favorable tolerability profile with no serious adverse events or liver toxicity, an estimated half‑life of about 24 days supporting once‑monthly dosing, and strong, sustained suppression of testosterone, follicle‑stimulating hormone and luteinizing hormone as biomarkers of target engagement. These findings supported advancing ABCL635 into a Phase 2 trial in postmenopausal women, with topline efficacy data expected in Q3 2026.